403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Briacell Therapeutics Corp.
(MENAFN- Baystreet) 10:03 AM EST - BriaCell Therapeutics Corp.: Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in nine cases as of their last assessment. BriaCell Therapeutics Corp.
shares T are trading down $0.03 at $6.35.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
Comments
No comment